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Abstract
BACKGROUND & AIMS—Polymorphisms in IL28B were shown to affect clearance of
hepatitis C virus (HCV) infection in genome-wide association (GWA) studies. Only a fraction of
patients with chronic HCV infection develop liver fibrosis, a process that might also be affected
by genetic factors. We carried out a 2-stage GWA study of liver fibrosis progression related to
HCV infection.
METHODS—We studied well-characterized HCV-infected patients of European descent who had
liver biopsies before treatment. We defined various liver fibrosis phenotypes on the basis of
Metavir scores, with and without taking the duration of HCV infection into account. Our GWA
analyses were conducted on a filtered primary cohort of 1161 patients using 780,650 single
nucleotide polymorphisms (SNPs). We genotyped 96 SNPs with P-values<5×10−5 from an
independent replication cohort of 962 patients. We then assessed the most interesting replicated
SNPs using DNA samples collected from 219 patients who participated in separate GWA studies
of HCV clearance.
RESULTS—In the combined cohort of 2342 HCV-infected patients, the SNPs rs16851720 (in the
total sample) and rs4374383 (in patients that received blood transfusions) were associated with
fibrosis progression (Pcombined=8.9×10−9 and 1.1×10−9, respectively). The SNP rs16851720 is
located within RNF7, which encodes an antioxidant that protects against apoptosis. The SNP
rs4374383, together with another replicated SNP, rs9380516 (Pcombined=5.4×10−7), were linked to
the functionally related genes MERTK and TULP1, which encode factors involved in
phagocytosis of apoptotic cells by macrophages.
CONCLUSIONS—Our GWA study identified several susceptibility loci for HCV-induced liver
fibrosis; these were linked to genes that regulate apoptosis. Apoptotic control might therefore be
involved in liver fibrosis.
Keywords
genetic analysis; risk factors; cirrhosis; liver disease
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Introduction
End-stage chronic hepatitis C is the leading cause of liver transplantation in developed
countries and more than 350,000 people die from HCV-related liver diseases each year.1
The natural course of chronic HCV infection is characterized by high levels of inter-
individual variation in disease progression.2 Most subjects never develop cirrhosis, but some
may develop severe fibrosis in less than 20 years. A number of host demographic and
clinical characteristics, as well as viral factors, have been associated with the development
of HCV-related liver fibrosis.2–4 However, these factors account for only a small proportion
of the variability in the rate of liver fibrosis development, which overall remains
unpredictable. There is accumulating evidence to suggest that host genetic factors are
involved, although these factors remain largely unknown.2,5 A number of candidate gene
approaches have been used in attempts to identify variants influencing the development of
liver disease in HCV-infected patients, but most of these studies produced results that were
not consistently replicated.5,6 Two related studies7,8 investigating ~25,000 putative
functional SNPs identified a panel of SNPs predicting the risk of developing cirrhosis; this
panel requires validation in prospective studies.8 A recent study of 36 candidate genes,
related to the fibrogenesis/fibrolysis process, identified a single cluster of variants of the
IFNGR2 gene associated with progression to severe fibrosis.9 The results of these studies
are interesting, but their approach may have prevented identification of genes strongly
associated with liver fibrosis present in parts of the genome not tested.
Genome-wide association (GWA) studies provide a broader and unbiased approach for the
discovery of genetic factors involved in disease susceptibility.10 For example, GWA studies
identified a SNP cluster in the IL28B gene with a major effect on HCV clearance, either
treatment-induced or spontaneous, whereas this gene had never previously been implicated
in HCV infection.11 A recent candidate gene study found that IL28B alleles associated with
poor HCV clearance had a protective effect against liver inflammation and fibrosis.12 No
GWA study has yet explored genetic susceptibility to liver fibrosis in patients with chronic
HCV infection. Several GWA studies of liver disease-related traits demonstrated a role for a
non-synonymous variant of the PNPLA3 gene, rs738409 (I148M), in the development of
nonalcoholic and alcoholic fatty liver disease and associated disease severity.13–15 The same
PNPLA3 risk allele was recently associated with steatosis and liver fibrosis in patients with
chronic HCV infection.16,17 In this study, we carried out a two-stage GWA study (primary
screen followed by a replication study) in a combined cohort of 2,342 well characterized
HCV-infected patients, to identify genetic factors influencing the development of HCV-
related liver fibrosis.
Patients & Methods
Patient Subjects
The sample used for the primary screen combined data from two cohorts of adult patients of
European descent from France and Switzerland with chronic HCV infection. We retained
only patients who had liver biopsy before treatment. The French cohort (ANRS Genoscan
study group) included patients from the hepatology units of several hospitals in Paris and
Marseilles; the inclusion criteria applied, including no co-infection by HIV or HBV, have
been described elsewhere.9 The Swiss Hepatitis C Cohort Study (SCCS) is a multicenter
study of HCV-infected patients enrolled at eight major Swiss hospitals and the affiliated
local centers. SCCS patient selection and data collection have also been described
elsewhere,3,18 and patients with known HIV or active HBV co-infection were excluded for
the present study. In total, 1,223 patients (490 from the French cohort and 733 from the
SCCS) were eligible for genetic analyses. We studied three additional cohorts of European-
descent adult patients with chronic HCV infection and not co-infected with HIV or HBV,
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with the aim of replicating the principal signals obtained in the primary cohorts. All 962
patients included in these cohorts had biopsy before treatment (Supplementary Table 1). A
first cohort of 64 US patients was recruited at the Weill-Cornell Medical Center in New
York, and a second sample of 256 French patients was recruited from different hospitals in
Marseilles. The third replication cohort included 642 patients recruited from centers in
Australia, Germany, the United Kingdom and Italy, as described elsewhere.19,20 Finally, the
seven signals showing evidence of true replication in the cohort combining primary and
replication cohorts were also tested in an additional independent sample of Australian
patients consisting of the primary cohort of a previous GWA study of response to hepatitis C
treatment.19 After excluding Australian patients with missing phenotype data, 219
individuals were kept for this analysis (Supplementary Table 1). Clinical risk factors, history
of HCV acquisition and of alcohol consumption (assessed using time-line follow back
interview) were recorded in the corresponding cohorts through face-to-face interviews
conducted by physicians trained in addiction problems. The sampling of all the cohorts was
approved by the appropriate institutional review boards, and written informed consent was
obtained from all patients.
Determination of Liver Fibrosis Phenotypes
The stage of liver fibrosis in patients with chronic HCV infection was determined by
examination of a liver biopsy specimen obtained before treatment, with quantification
according to the Metavir score, on a five-point scale from F0 to F4.21 Fibrosis was assessed
by experienced pathologists working in the local expert liver centers corresponding to the
place of collection, and all biopsies were considered as interpretable by each local
pathologist. Metavir scoring system is validated since many years and highly reproducible
for pathologists specialized in liver disease.22 For each patient, we used the information
obtained from a single biopsy, referred to as the reference biopsy. For patients who had
undergone several biopsies, the reference biopsy was defined as follows: (i) the most recent
biopsy obtained in the absence of treatment for patients who had not spontaneously
developed fibrosis, i.e. all biopsy results without treatment were F0 or F1; (ii) the biopsy
with the highest Metavir score for patients who had developed fibrosis, i.e. at least one
biopsy result ≥F2; the earliest biopsy was selected if there were several biopsies with the
highest score. We used three different approaches to define liver fibrosis phenotype on the
basis of the Metavir score for the reference biopsy. The first of these approaches was a
classic case/control approach in which F0-1 patients were considered as controls and F3-4
patients, as cases. Patients with an intermediate Metavir score (F2) were discarded for this
analysis, which was thus a binary F0-1/F3-4 phenotype analysis. Within this approach, we
also used a more extreme definition of the phenotypes, in which we considered only F0
patients as controls and F4 patients as cases (binary F0/F4 phenotype analysis). In the
second approach, we used survival analysis techniques to take into account the individual
duration of infection in the analysis. Failure (F3-4 or only F4) and censored (F0-1 or only
F0) events were defined as in the case/control study, and the duration of infection was
estimated from the presumed year of HCV acquisition to the year in which the biopsy was
carried out. The estimated date of HCV acquisition was obtained using the first reported
major event at risk among blood transfusion, drug use (the first year of injecting drug use
(IDU) was used as the starting point), accidental needle stick or other invasive medical
procedures. In this analysis, the phenotype is denoted duration F0-1/F3-4 or duration F0/F4.
In the third approach, liver fibrosis progression was considered as a quantitative phenotype,
fibrosis progression rate (FPR), corresponding to the ratio of Metavir score to the estimated
duration of infection in years (Metavir units per year).23,24 Patients with a F2 Metavir score
were included in this analysis. Given the distribution of FPR, this phenotype was log-
transformed and then inverse normal quantile-transformed in each cohort before statistical
analysis. The resulting phenotype, denoted as QTF phenotype, was further standardized such
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that the differences in mean QTF rates between genotypes for a given SNP could be
expressed in standard deviation units, referred to as standardized Metavir units (SMUs).
Posterior to the selection of the 96 followed-up SNPs (see next sections), we analyzed our
primary data by modeling transition probabilities between Metavir stages using a Markov
model, described in Supplementary Methods. This approach was not further considered,
because it provided no additional association signals with P values<5×10−6 in our primary
cohort, with respect to analyses using the three other phenotype definitions.
Genotyping and Imputation Procedures
Details of genotyping methods, quality controls and imputation procedures are provided in
the Supplementary Methods. Briefly, the French and Swiss primary cohorts were genotyped
for ~350,000 SNPs and ~1,000,000 SNPs, respectively, using Illumina HumanCNV370-Duo
and Human1M-Duo beadchips (Illumina, San Diego, USA). Quality-control filtering of
SNPs resulted in a total of 325,624 and 912,765 high-quality SNPs, respectively. Genotype
imputation was performed in the French primary cohort, using the Swiss cohort as a
template. This procedure yielded a total of 780,650 high-quality genotyped or imputed
SNPs, which were used for all analyses. Quality-control filtering was also carried out for
individuals, and 1,161 filtered individuals were used for GWA analyses (Table 1). The 962
subjects of the replication cohorts (Supplementary Table 1) were genotyped for 96 followed-
up SNPs by Illumina GoldenGate genotyping with VeraCode technology (Illumina), as well
as our French primary cohort for 33 out of the 96 SNPs that were initially imputed in this
cohort. Eighty-seven high-quality SNPs were tested for replication. Among the seven SNPs
showing evidence for true replication, two SNPs, rs16851720 and rs4374383, were not
present in the GWA cohort of 219 Australian patients, genotyped by the Illumina Infinium
HumanHap300 or the CNV370-Quad genotyping BeadChips (Illumina). We could impute
these two SNPs with a high accuracy of 0.996 and 0.984, respectively (Supplementary
Methods).
Statistical Analyses
For liver fibrosis considered as binary phenotypes, we used Fisher’s exact test and logistic
regression. For duration phenotypes, we used a Cox model considering estimated age at
infection as the starting point and the first biopsy showing severe fibrosis (failure time) or
the last biopsy showing an absence of severe fibrosis in the absence of treatment (censored
time) as the endpoint. Logistic regression and Cox model analyses were used for stratified
and multivariate adjusted analyses, with sex, HCV genotype, age at infection, alcohol
consumption and/or mode of HCV acquisition as covariates. For the QTF phenotype, linear
regression analysis was performed. All statistical analyses were carried out with procedures
implemented in SAS software v.8.2 (SAS Institute, Cary, North Carolina, USA), R software
(http://www.R-project.org/), Matlab (www.mathworks.com) and PLINK.25 The power of
this study was estimated for the binary F0-1/3–4 and the duration F0-1/3–4 phenotypes, as
described in Supplementary Methods.
As we conducted several analyses, using different phenotypes, genetic models and stratified
samples, we estimated the effective number of tests in our study by a method detailed in the
Supplementary Methods. Briefly, we estimated that the analyses conducted in the whole
sample corresponded to a total number of ~3 million effective tests. Adjusted and stratified
analyses were performed only on the binary and duration F0-1/F3-4 phenotypes, for the
140,797 SNPs giving P-values<0.05 in the analyses conducted on these two phenotypes in
the whole sample, taking eight strata into account: age at infection>20 years, age at
infection<20 years, male, female, contamination by transfusion, contamination by IDU,
HCV genotype=1 and HCV genotype≠1. The number of effective tests for these stratified
analyses was estimated at ~1.6 million, giving a total of ~4.9 million independent tests for
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our entire GWA analysis. We therefore considered P-values<10−8 (0.05/4.9×106) to indicate
genome-wide significance in our study.
Results
Genome-wide analyses in the primary cohort
GWA analyses were conducted on a filtered primary cohort of 1,161 HCV-infected patients
(Table 1), with a total of 780,650 SNPs. We first used the binary F0-1/F3-4 phenotype of
liver fibrosis and assumed an additive genetic model. No significant deviations from
expectations were observed on quantile-quantile plots before and after correction for
population stratification (Supplementary Figure 1), attesting to an absence of difference in
ancestry between cases and controls (genomic inflation factor λ=1.013). In addition, none of
the first 10 principal components of ancestry was associated with case-control status
(Supplementary Figure 2). We therefore carried out all subsequent analyses without
adjustment for population stratification.
Figure 1A shows the Manhattan plot obtained for analysis of the binary F0-1/F3-4
phenotype, for the best among the three genetic models tested (additive, recessive,
dominant). P-values<10−6 were obtained for two SNPs on chromosomes 2 and 8
(Supplementary Table 2). When restricting our cohort to the most extreme Metavir scores
(binary F0/F4 phenotype), a single locus on chromosome 2, tagged by four SNPs in strong
linkage disequilibrium (LD), achieved a P-value<10−6 (Supplementary Figure 3A and
Supplementary Table 2). We then carried out GWA analyses taking into account the
estimated duration of infection in 1,064 subjects for whom follow-up information was
available. Two SNPs on chromosomes 11 and 18 provided P-values<10−6 when considering
the duration F0-1/F3-4 phenotype (Figure 1B and Supplementary Table 2). When restricting
the analysis to the duration F0/F4 phenotype, a P-value<10−6 was obtained for one SNP on
chromosome 6 (Supplementary Figure 3B and Supplementary Table 2). Finally, the GWA
analysis of the QTF phenotype identified a single SNP on chromosome 3 with a P-
value<10−6 (Figure 1C and Supplementary Table 2). For all phenotypes, 45 additional
independent signals gave P-values<5×10−5 (Supplementary Table 3).
All the classical risk factors for fibrosis development available in our sample (i.e. sex,
alcohol consumption, HCV genotype, HCV mode of acquisition and age at infection) were
significantly and independently associated with fibrosis progression in our sample, in
multivariate logistic regression analysis (Supplementary Table 4). Multivariate analyses of
our binary and duration F0-1/F3-4 phenotypes adjusted for these factors did not substantially
change our previous results (Supplementary Table 3). We also performed adjusted and
stratified analyses for the binary and duration F0-1/F3-4 phenotypes, using the 140,797
SNPs that achieved a P-value<0.05 in one of these two analyses. These analyses were
performed taking into account binarized covariables such as sex (male/female), HCV
genotype (1/others) or mode of acquisition (blood transfusion/IDU). In analyses with the
duration F0-1/F3-4 phenotype, six SNPs gave P-values<10−6, including three with P-
values<10−7 (Supplementary Table 2). In total, 38 additional independent signals gave P-
values<5×10−5 (Supplementary Table 3).
Replication study
In the second phase, we genotyped a total of 96 independent SNPs presenting a P-
value<5×10−5 in one of our previous GWA analyses (Supplementary Table 3) in a
replication cohort of 962 HCV-infected patients (Supplementary Table 1). Eighty-seven of
these SNPs satisfying the quality-control filters were tested for association. Evidence for
true replication (using the same model as in the primary analysis) at the 0.05 level was
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obtained for seven SNPs (Table 2). We further tested these seven SNPs in an additional
filtered cohort of 219 Australian patients with liver biopsy data (Supplementary Table 1),
who were previously genotyped for ~310,000 SNPs on Illumina beadchips in a GWA study
of response to chronic hepatitis C treatment.19 Out of these seven SNPs, two (rs16851720
and rs4374383) were not present on the arrays, and were successfully imputed in this
Australian cohort (Patients & Methods).
The combined analysis of these seven SNPs in the total sample of 2,342 patients identified
two SNPs (Table 2) with P-values below our estimated genome-wide threshold for
significance of 10−8 (see Patients & Methods for details). Tests of heterogeneity across
primary and replication cohorts were not significant for either of these SNPs (Table 2). SNP
rs16851720 provided a combined P-value=8.9×10−9 in the whole sample, in the analysis of
the QTF phenotype (additive for C, difference between genotypes of 0.23 SMU (0.15–0.31);
Figure 2A). This intronic SNP is located in RNF7 (Supplementary Figure 4A), encoding a
redox-inducible antioxidant protein that protects against apoptosis.26 The second SNP was
rs4374383, with P-value=1.1×10−9 in blood-transfused patients in analysis of the duration
F0-1/F3-4 phenotype (recessive for minor allele A, hazard ratio of developing liver fibrosis
(HR) for AA vs.AG/GG=0.18 (0.09–0.36); Figure 2B). We found that this association was
independent of viral genotypes (data not shown) although blood-transfused patients are more
often infected with HCV genotypes 1 and 2. SNP rs4374383 is intronic in the MERTK gene
(Supplementary Figure 4B), a member of the three TAM receptor tyrosine kinases which are
involved in the regulation of inflammatory responses.27
Out of the five remaining replicated SNPs, two were improved or unchanged by the addition
of the Australian cohort (Table 2). One was rs2629751 in analysis of the binary F0/F4
phenotype (P=1.4×10−7; recessive for G, OR=7.10 (2.94–20.74); Figure 2C), which is
intronic in the GLT8D2 gene. The other signal was identified using the duration F0-1/F3-4
phenotype in men at SNP rs9380516 (P=5.4×10−7; recessive for T, HR=4.53 (2.78–7.39);
Figure 2D), which is located 21 kb downstream from the TULP1 gene. The last three signals
(SNPs rs883924, rs7800244 and rs6485480) were clearly less significant when the data for
the Australian cohort were included in the analysis (Table 2). Consistent with this
observation, tests of heterogeneity across cohorts were close to significance (P=0.06) and
significant (P=0.01) for rs7800244 and rs6485480, respectively (Table 2).
Finally, we assessed, in our primary cohort, the association of liver fibrosis with a number of
variants reported in large association studies (GWA studies or investigations of a large
number of genes) to be associated with either liver fibrosis-related phenotypes in non HCV
patients or other HCV-related phenotypes (Supplementary Table 5). Using the same
methods as two previous studies partly overlapping with our primary cohort, we found that
rs9976971 in IFNGR2 9 and rs8099917 in IL28B 12 were associated with liver fibrosis, with
P-values of 0.009 and 0.018, respectively. We found no significant effect of variants
reported to be associated with liver fibrosis in Caucasian patients with chronic HCV
infection,7,8 with liver fibrosis in Spanish patients with non-alcoholic fatty liver disease28 or
with the development of hepatocellular carcinoma in HCV-infected Japanese patients.29,30
However, we found that rs738409 in PNPLA3 was associated with liver fibrosis in our
primary cohort, in analyses with the binary F0-1/F3-4 phenotype (additive model for allele
G, P=1.3×10−4, OR=1.21 (1.10–1.34)). The non-synonymous PNPLA3 variant rs738409 has
been shown to be associated with several liver-related traits in GWA studies,13–15 and with
liver steatosis and fibrosis in patients chronically infected with HCV in studies based on
candidate gene approaches.16,17,31
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Discussion
We report the first GWA study investigating liver fibrosis progression in a large sample of
more than 2,300 HCV-infected patients of European descent. For all patients, liver biopsy
data were obtained before treatment. We defined several fibrosis phenotypes on the basis of
histological findings, because the Metavir system grading is not linear,21 and because we
wished to investigate various and complementary aspects of the fibrosis process. In this
context, we also sought to use an additional, more sophisticated approach, involving a
Markov model of the probability of transition between Metavir stages (Supplementary
Methods). This approach provided no additional signals with P values<5×10−6 for our
primary cohort (data not shown). Overall, our analyses covered a large panel of liver fibrosis
phenotypes in a well characterized sample of HCV-infected patients, and identified four
replicated signals including two that were significant at the genome-wide level in the
combined cohort.
Gene ontology enrichment analysis of our four most interesting signals revealed significant
enrichment for two categories, “photoreceptor outer segment” and “phagocytosis”
(P=5×10−4 and P=5×10−3, respectively, after Bonferroni correction; Supplementary
Methods). This result is explained by two SNPs: rs4374383, our most significant signal, and
rs9380516, located within or close to MERTK and TULP1, respectively. Interestingly,
rs4374383 is in strong LD (r2>0.9, measured using HapMap phase II data in the CEU
European-descent population) with two MERTK non-synonymous SNPs, rs7604639 and
rs3811635, and rs9380516 is in strong LD (r2=0.9 in CEU) with an intronic SNP of TULP1,
rs9296155. Although Mendelian defects of these two genes affect only the retina,32–34 both
genes have a broader spectrum of expression, with TULP1 expressed in the fetal liver35 and
MERTK expressed in macrophages.27 In addition, the MERTK and TULP1 proteins have
been shown to interact during the phagocytosis of apoptotic cells.36 In particular, mice
lacking specifically the murine homolog of MERTK display a deficiency in the clearance of
apoptotic thymocytes by macrophages.37 Interestingly, the clearance of apoptotic debris by
phagocytosis can directly stimulate fibrogenesis.38,39 Hepatic stellate cells (HSC) may play
a key role in this process, as they have phagocytic functions, including the NADPH oxidase
activity required for the production of reactive oxygen species (ROS).40 HSC are also found
in close proximity to hepatocytes, a key source of apoptotic debris during liver injury.41
Overall, our results suggest a possible relationship between the clearance of apoptotic cells
through phagocytosis and liver fibrosis.
The second signal significant at the genome-wide level was that for SNP rs16851720 in the
whole sample. The effect of this SNP on fibrosis progression rate (FPR) was clearly additive
in our combined cohort (Figure 2A). If FPR means were calculated directly as a function of
rs16851720 genotypes, we found that each A risk allele increased the rate of liver fibrosis
progression by 0.033 Metavir units/year, corresponding to ~1 Metavir unit over a 30-year
period. This SNP is located in the first intron of RNF7, which is also known as SAG
(sensitive to apoptosis gene). RNF7 is a cell-protecting molecule that acts as an antioxidant,
inhibiting the apoptosis induced by metal ions and ROS,26 thereby preventing DNA
damage.42 In this context, it is interesting to note that HCV inhibits host DNA damage
repair through ROS production.43 The induction of these processes, including high levels of
ROS production in particular, in HCV-infected cells leads to hepatocyte apoptosis and HSC
activation, and may also contribute to the development of liver fibrosis44 through
mechanisms described above.
In conclusion, for the whole sample, we found a genome-wide significant effect of the SNP
rs16851720 on liver fibrosis, and confirmed the role of the PNPLA3 non-synonymous
I148M variant. We also found some interesting additional signals, including one genome-
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wide significant, in more refined subsamples, which require further investigation. Overall,
our findings suggest that several variants in a number of genes with rather modest effects (in
the whole sample) and/or more complex effects (e.g. limited to a specific subsample) may
be involved in genetic susceptibility to liver fibrosis secondary to chronic HCV infection.
They also point out the role of apoptosis potentially providing new insights into the
mechanisms underlying liver fibrosis development.41,45
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Manhattan plots of genome-wide analyses of liver fibrosis using (A) the binary F0-1/F3-4
phenotype (949 F0-1/F3-4 patients), (B) the duration F0-1/F3-4 phenotype (872 F0-1/F3-4
patients with available duration of infection) and (C) the QTF phenotype (1,064 patients
with available duration of infection). Larger points correspond to SNPs producing a P-
value<10−6. All the analyses were performed on 780,650 genotyped or imputed SNPs
(Patients & Methods).
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Figure 2.
Genotype/phenotype relationships for the four SNPs most associated with liver fibrosis in
the final combined cohort. (A) Standardized Metavir units (SMU; Patients & Methods) for
the three genotypes of SNP rs16851720 (located within RNF7), identified using the QTF
phenotype. Bars represent standard errors (SEM) of each mean SMU. Genotype AA was
used as the reference (SMU=0). (B) Survival curves for SNP rs4374383 (located within
MERTK) identified using the duration F0-1/F3-4 phenotype, in the subsample of transfused
patients. (C) Proportions of all HCV-infected patients with Metavir scores of F0 and F4, by
genotype at rs2629751 (located within GLT8D2), a replicated SNP identified using the
binary F0/F4 phenotype. (D) Survival curves for SNP rs9380516 (located near TULP1), a
replicated SNP identified using the duration F0-1/F3-4 phenotype stratified in male patients.
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